Cargando…
E-cadherin expression as a prognostic factor in patients with ovarian cancer: a meta-analysis
The prognostic role of epithelial cadherin (E-cadherin) downregulation in ovarian cancer has been assessed for years while the results remain inconclusive. The aim of our study was to assess this issue. Eligible studies were identified through searches of PubMed, EMBASE and Cochrane Database. In tot...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655261/ https://www.ncbi.nlm.nih.gov/pubmed/29113366 http://dx.doi.org/10.18632/oncotarget.18898 |
_version_ | 1783273499699183616 |
---|---|
author | Dai, Chencheng Cao, Jian Zeng, Yu Xu, Sujuan Jia, Xuemei Xu, Pengfei |
author_facet | Dai, Chencheng Cao, Jian Zeng, Yu Xu, Sujuan Jia, Xuemei Xu, Pengfei |
author_sort | Dai, Chencheng |
collection | PubMed |
description | The prognostic role of epithelial cadherin (E-cadherin) downregulation in ovarian cancer has been assessed for years while the results remain inconclusive. The aim of our study was to assess this issue. Eligible studies were identified through searches of PubMed, EMBASE and Cochrane Database. In total, 1562 patients from 17 studies were included to assess the association between E-cadherin expression and overall survival/progression-free survival and clinicopathological characteristics of ovarian cancer patients. Hazard ratios (HRs) or odds ratios (ORs) with 95% confidence interval (95% CI) were calculated to estimate the effect. The quality of 17 studies was evaluated using the Newcastle Ottawa Quality Assessment Scale. We also performed subgroup analysis, publication bias and sensitivity analysis in this meta-analysis. The results showed that negative E-cadherin expression significantly predicted poor overall survival of ovarian cancer patients (HR = 1.90, 95% CI = 1.50–2.40). However, negative E-cadherin was not associated with poor progression-free survival (HR = 1.19, 95% CI = 0.86–1.64). Moreover, Negative E-cadherin expression was distinctly associated with FIGO stage (OR = 0.42, 95% CI = 0.31–0.57), tumor grade (OR = 0.48, 95% CI = 0.34–0.67), metastasis (OR = 0.13, 95% CI = 0.07–0.26) and recurrence (OR = 0.48, 95% CI = 0.29–0.79). This meta-analysis revealed that negative E-cadherin expression might be a predicative factor of poor prognosis in ovarian cancer patients. |
format | Online Article Text |
id | pubmed-5655261 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-56552612017-11-06 E-cadherin expression as a prognostic factor in patients with ovarian cancer: a meta-analysis Dai, Chencheng Cao, Jian Zeng, Yu Xu, Sujuan Jia, Xuemei Xu, Pengfei Oncotarget Meta-Analysis The prognostic role of epithelial cadherin (E-cadherin) downregulation in ovarian cancer has been assessed for years while the results remain inconclusive. The aim of our study was to assess this issue. Eligible studies were identified through searches of PubMed, EMBASE and Cochrane Database. In total, 1562 patients from 17 studies were included to assess the association between E-cadherin expression and overall survival/progression-free survival and clinicopathological characteristics of ovarian cancer patients. Hazard ratios (HRs) or odds ratios (ORs) with 95% confidence interval (95% CI) were calculated to estimate the effect. The quality of 17 studies was evaluated using the Newcastle Ottawa Quality Assessment Scale. We also performed subgroup analysis, publication bias and sensitivity analysis in this meta-analysis. The results showed that negative E-cadherin expression significantly predicted poor overall survival of ovarian cancer patients (HR = 1.90, 95% CI = 1.50–2.40). However, negative E-cadherin was not associated with poor progression-free survival (HR = 1.19, 95% CI = 0.86–1.64). Moreover, Negative E-cadherin expression was distinctly associated with FIGO stage (OR = 0.42, 95% CI = 0.31–0.57), tumor grade (OR = 0.48, 95% CI = 0.34–0.67), metastasis (OR = 0.13, 95% CI = 0.07–0.26) and recurrence (OR = 0.48, 95% CI = 0.29–0.79). This meta-analysis revealed that negative E-cadherin expression might be a predicative factor of poor prognosis in ovarian cancer patients. Impact Journals LLC 2017-06-30 /pmc/articles/PMC5655261/ /pubmed/29113366 http://dx.doi.org/10.18632/oncotarget.18898 Text en Copyright: © 2017 Dai et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Meta-Analysis Dai, Chencheng Cao, Jian Zeng, Yu Xu, Sujuan Jia, Xuemei Xu, Pengfei E-cadherin expression as a prognostic factor in patients with ovarian cancer: a meta-analysis |
title | E-cadherin expression as a prognostic factor in patients with ovarian cancer: a meta-analysis |
title_full | E-cadherin expression as a prognostic factor in patients with ovarian cancer: a meta-analysis |
title_fullStr | E-cadherin expression as a prognostic factor in patients with ovarian cancer: a meta-analysis |
title_full_unstemmed | E-cadherin expression as a prognostic factor in patients with ovarian cancer: a meta-analysis |
title_short | E-cadherin expression as a prognostic factor in patients with ovarian cancer: a meta-analysis |
title_sort | e-cadherin expression as a prognostic factor in patients with ovarian cancer: a meta-analysis |
topic | Meta-Analysis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655261/ https://www.ncbi.nlm.nih.gov/pubmed/29113366 http://dx.doi.org/10.18632/oncotarget.18898 |
work_keys_str_mv | AT daichencheng ecadherinexpressionasaprognosticfactorinpatientswithovariancancerametaanalysis AT caojian ecadherinexpressionasaprognosticfactorinpatientswithovariancancerametaanalysis AT zengyu ecadherinexpressionasaprognosticfactorinpatientswithovariancancerametaanalysis AT xusujuan ecadherinexpressionasaprognosticfactorinpatientswithovariancancerametaanalysis AT jiaxuemei ecadherinexpressionasaprognosticfactorinpatientswithovariancancerametaanalysis AT xupengfei ecadherinexpressionasaprognosticfactorinpatientswithovariancancerametaanalysis |